钙释放激活钙调素 1 作为变应性皮肤病的治疗靶点。
Calcium release-activated calcium modulator 1 as a therapeutic target in allergic skin diseases.
机构信息
Department of Dermatology, Xiangya Hospital, Central South University, Changsha,Hunan, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Engineering Research Center of Skin Health and Disease, Changsha, Hunan, China.
Department of Dermatology, Xiangya Hospital, Central South University, Changsha,Hunan, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China; Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
出版信息
Life Sci. 2019 Jul 1;228:152-157. doi: 10.1016/j.lfs.2019.05.001. Epub 2019 May 2.
Allergic skin disease is the most common skin condition, and considerably affects patients' life quality because of its recurrence and pruritus. Numbers of studies point out that immune cells, including mast cells and T cells, play pathogenic roles in allergic skin diseases, and share similarities in the activation and secretion of cytokines. Calcium Release-Activated Calcium Modulator 1(CRACM1/ORAI1) is a subtype of Ca membrane channel, causing Ca influx into the cells. As a second messenger, Ca is an essential element that regulates immune responses, especially in the development and function of T and B cells. Thus, ORAI1 is considered to participate in allergic diseases. However, the specific mechanism of ORAI1 in skin disorders is still unclear. In order to investigate the roles of ORAI1 in allergic skin disorders, we reviewed the related articles and concluded that ORAI1 could be a potential therapeutic target for allergic skin diseases.
变应性皮肤病是最常见的皮肤病，由于其反复发作和瘙痒，严重影响患者的生活质量。大量研究指出，免疫细胞（包括肥大细胞和 T 细胞）在变应性皮肤病中发挥致病作用，细胞因子的激活和分泌具有相似性。钙释放激活钙调蛋白 1（CRACM1/ORAI1）是钙膜通道的一种亚型，导致钙内流进入细胞。作为第二信使，钙是调节免疫反应的必需元素，尤其是在 T 和 B 细胞的发育和功能中。因此，ORAI1 被认为参与了变应性疾病。然而，ORAI1 在皮肤疾病中的具体作用机制尚不清楚。为了探讨 ORAI1 在变应性皮肤疾病中的作用，我们查阅了相关文献，得出结论：ORAI1 可能是治疗变应性皮肤疾病的潜在靶点。
Zotero 插件